T he fact that chemical modifications to DNA bases can alter gene expression without changing the nucleic-acid sequence has been known for more than a decade. But the key regulatory function of many such epigenetic modifications to messenger RNA molecules has been recognized only recently [1] [2] [3] . A simple mark -the methyl group -is widely observed in DNA and its associated histone proteins, and has been studied in mRNA in the forms of 5-methylcytosine and N 6 -methyladenosine. On page 441 of this issue, Dominissini et al. 4 present a new member of the mRNA methylmarked family, N 1 -methyl adenosine, and propose that its presence in mRNAs has an influence on biological processes. What is surprising about this modification is that it has previously been described as a form of cellular damage 5 .
N
1 -methyladenosine (m 1 A) is unusual in having a positive charge at physiological pH (other bases are uncharged) and a methyl group that blocks the Watson-Crick basepairing edge of adenine. The modification was previously documented in transfer RNA molecules, where it plays a crucial part in the formation of tertiary RNA structure. The methyl group forces the m 1 A base to pair with a non-Watson-Crick configuration 6 , and the positive charge has also been hypothesized to exert an electrostatic influence on protein interactions 7 . Dominissini et al. propose that this base modification may have similar biophysical effects in mRNAs: it could affect base-pairing inter actions close to the site at which protein translation starts, and might alter RNA folding and electrostatic interactions. m 1 A was previously known to be formed by the exposure of RNA molecules to alkylating agents, and under alkaline conditions it is converted to N 6 -methyladenosine (m 6 A) through the Dimroth rearrangement 8 ( Fig. 1) . This is potentially a big problem in analysis, T R 1-like cells induced by pMHC-NP treatment? Clemente-Casares et al. show that the cells suppress the function of APCs and reinforce immune regulation by promoting IL-10 production by B cells (Fig. 1) . The authors verify the specificity of their approach by using different experimental models of autoimmune disease. pMHC-NPs carrying peptides from collagen, an antigen derived from joints, suppressed disease in a mouse model of rheumatoid arthritis, but not in mice with experimental autoimmune encephalitis (EAE), a model of multiple sclerosis. Conversely, pMHC-NPs carrying peptides of antigens from the central nervous system controlled EAE but not collagen-induced arthritis. This confirms that the immune regulation induced by pMHC-NP treatment is specific to the antigen and tissue, and so to the disease.
Furthermore, the pMHC-NPs did not need to target T cells specific for all peptides in the affected organ. Even peptides from sub-dominant antigens (weaker antigens that do not trigger disease in the first place) were able to induce T R 1-like cells that suppressed helper and cytotoxic T cells with activity against other antigens (Fig. 1) . Thus, although this treatment is highly antigen-specific at the induction phase, it can influence other arms of the immune response locally, through induction of regulatory B-cell activity and suppression of helper and cytotoxic T cells specific for different antigens. This requires that the peptide fragment from the inducing antigen and the other antigens are presented by the same APC.
Is it possible that such bystander suppression could lead to systemic immune suppression by switching off cells not involved in the autoimmune response, thereby increasing the risk of infection or cancer? No: bystander suppression will be limited to lymph nodes associated with the affected organ and will influence only those APCs presenting the relevant self-antigen. Such specificity is clearly demonstrated by Clemente-Casares and colleagues -mice treated with pMHC-NPs are protected against the relevant autoimmune disease, yet show undiminished responses to infections and foreign antigens.
The experimental treatments in this study use well-characterized models of autoimmune disease. But is this work just another therapeutic approach that works in mice but will never work in humans? It seems not: the authors show that pMHC-NP treatment leads to differentiation and proliferation of human T R 1-like cells in immunodeficient mice transplanted with human T and B cells, demonstrating that pMHC-NP treatment works on human cells. The team's work also suggests that treatment with pMHC-NPs is more effective than with monomers of MHC-bound peptides at an equivalent dose. Furthermore, pMHC-NP treatment seems to be more suppressive than the application of peptide alone; however, the doses and routes of administration in these tests were not comparable.
There is overwhelming evidence that peptide antigens can induce T R 1-like cells 11 and suppress autoimmune diseases in both mice and humans 9 . The fact that pMHC-NP treatment induces T R 1-like cells similar to those seen after the administration of peptide alone suggests that pMHC-NPs mimic the APC to which therapeutic peptides bind in vivo. The challenge with each of these approaches will be to find the optimal dose and route of administration for treating people. As these options progress towards clinical trials, it is vital that their mechanism of action is investigated in detail so that patients can benefit fully from antigen-specific immunotherapy for auto immune disease. ■ A. Through carefully controlled sample preparation, they reduced the incidence of the m 1 A-to-m 6 A rearrangement to less than 10%, and the use of an isotopically labelled internal control during mass-spectrometry analysis allowed them to accurately quantify m 1 A. These techniques enabled the researchers to identify the overall amounts of the modification in cells, and to map its locations in mRNAs.
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The authors find that, although the N 1 methyl ation of adenine occurs several times less often than N 6 methylation, it is still found in thousands of mRNAs. They note an enrichment of m 1 A signals near the translational start site of these mRNAs, and most of the molecules analysed were methylated only once, suggesting that the group has a single role in a given RNA. In the same region, they found sequences rich in the bases guanine and cytosine; such GC-rich motifs correlate with thermodynamically stable secondary RNA structure, which could be involved in directing the placement of m A key question raised by these findings is how the cell differentiates between damage and intentional, stable cellular markers. When is m 1 A a 'bug' , and when is it a useful feature? Methylation of adenine at position 1 is well documented to arise from exposure to chemical methylating agents 9 ( Fig. 1) , and thus 1-methyladenine has been widely studied as a form of damage in DNA and RNA. At least one enzyme (ALKBH3) has been documented to remove this lesion and reduce its cytotoxicity 10 . A recent study that also documents m 1 A in non-damaged mRNAs shows explicitly that this 'repair' enzyme can remove much of this methyl mark 11 . It will be important to determine how the stable m Dominissini and colleagues' findings represent an intriguing step for epitranscriptomics. More work is needed to understand the mechanism by which m 1 A influences translation initiation and regulation, as well as the changes in its levels in stress responses. It will be exciting to see how this modification affects, and is affected by, RNA structure. Moreover, we need to know about the hypothesized proteins that are 'writers' , 'readers' and 'erasers' of m 1 A and thus take part in the dynamics of its regulation. Finally, as yet another modified base has been identified in mRNAs, one wonders how many more exist: is this the final one, or are we just seeing the tip of the epitranscriptome iceberg? ■ Anna M. Kietrys . Dominissini et al. 4 report the presence of m 1 A in undamaged messenger RNA molecules, and propose that it represents a cellular epigenetic mark. In response to damage, the repair enzyme ALKBH3 can remove this methyl group to repair the base, but it is not clear if this or other enzymes function to remove the mark in an epigenetic context, nor how this mark is added 
